Premium
Interim FDG ‐ PET has no value in selecting patients who require treatment modification in both early‐ and advanced‐stage Hodgkin lymphoma
Author(s) -
Adams Hugo J. A.,
Kwee Thomas C.
Publication year - 2018
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.14906
Subject(s) - abvd , medicine , dacarbazine , procarbazine , vinblastine , vincristine , b symptoms , oncology , lymphoma , nuclear medicine , chemotherapy , cyclophosphamide
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom